Search clinical trials for: Selumetinib, 125mg

Total 715 results

Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Solid Tumors

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
National Cancer Institute (NCI)

Withdrawn

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Nerve Tissue | Peripheral Nervous System Diseases | Heredodegenerative Disorders, Nervous System | Neurofibromatosis 1
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

United States
AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Solid Tumours

United Kingdom
AstraZeneca

Completed

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Healthy Volunteers Bioavailability Study

United Kingdom
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE)

Neurofibromatosis Type 1

United States, Spain, Germany, Netherlands, Russian Federation, Italy, Japan
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
AstraZeneca

Approved for marketing

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NF type1 With Inoperable Plexiform Neurofibromas

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

Solid Tumours

United States
AstraZeneca

Withdrawn

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study (PROTECT)

Neurofibromatosis Type 1 | Plexiform Neurofibromas | Post-operative

China
The Christie NHS Foundation Trust
AstraZeneca; University of Manchester

Completed

MEK Inhibitor and Thoracic Radiotherapy Trial (MEKRT)

Non Small Cell Lung Cancer

United Kingdom
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Neurofibromatosis Type 1

United States, Spain, Poland, Russian Federation
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

Healthy Volunteers Bioequivalence or Bioavailability Study

United Kingdom
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Children's Hospital Medical Center, Cincinnati
AstraZeneca

Active, not recruiting

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)

Glioma | Ependymoma | Meningioma | Neurofibromatosis 2 | Vestibular Schwannoma

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Solid Tumor | Idiopathic Pulmonary Fibrosis(IPF)

China
AstraZeneca

Completed

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Solid Tumours

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Myelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative Neoplasms

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Neurofibromatosis 1 | Neurofibroma Plexiform

China
AstraZeneca

Completed

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

Healthy Volunteers Pharmacokinetic Study

United Kingdom
Corcept Therapeutics

Completed

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Primary Peritoneal Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor

United States
HK inno.N Corporation

Enrolling by invitation

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Healthy

Korea, Republic of
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Optic Nerve Glioma

United States
AstraZeneca

Completed

Selumetinib Paediatric NF1 Japan Study

Neurofibromatosis Type 1

Japan
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Cancer | Non Small Cell Lung Cancer

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
AstraZeneca

Completed

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Neurofibromatosis Type 1 | Optic Nerve Glioma | Plexiform Neurofibroma

United Kingdom
Napo Pharmaceuticals, Inc.

Completed

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Acquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV Diarrhea

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
National Cancer Institute (NCI)

Completed

Selumetinib in Cancers With BRAF Mutations

Adult Solid Neoplasm

United States
Krzysztof Misiukiewicz
Sanofi; Icahn School of Medicine at Mount Sinai

Completed

Cabazitaxel - PF Induction Chemotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
National Cancer Institute (NCI)

Completed

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | KRAS NP_004976.2:p.G12R

United States
Paddock Laboratories, Inc.

Completed

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

Healthy

United States
Haihe Biopharma Co., Ltd.

Completed

Single Dose Glumetinib in Healthy Chinese Male Subjects

Healthy Volunteers

China
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Cefprozil Granule in Healthy Chinese Volunteers

Healthy Volunteers

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Liver and Intrahepatic Biliary Tract Cancer

United States
Sheffield Teaching Hospitals NHS Foundation Trust
AstraZeneca; University of Sheffield; Cancer Research UK; University of Birmingham and other collaborators

Terminated

A Study of Selumetinib in Patients With Kaposi's Sarcoma (SCART)

AIDS-related Kaposi's Sarcoma

United Kingdom

Search clinical trials for: Selumetinib, 125mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations